KORU Medical Systems, Inc. announced a development agreement with a biopharmaceutical manufacturer for KORU Medical to develop and seek regulatory approval for a next-generation infusion system for its subcutaneous immunoglobulin (SCIg) therapy.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.35 USD | +5.38% |
|
+3.52% | -4.28% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-4.28% | 102M | |
-3.18% | 181B | |
-2.68% | 105B | |
-2.23% | 67.55B | |
-6.46% | 46.39B | |
+4.82% | 40.93B | |
+20.09% | 31.63B | |
+12.18% | 24.28B | |
-6.67% | 23.46B | |
-12.70% | 21.95B |
- Stock Market
- Equities
- KRMD Stock
- News KORU Medical Systems, Inc.
- KORU Medical Systems, Inc. Announces Development Agreement for Next-Generation Subcutaneous Immunoglobulin Infusion System